IRIS
GALEAZZI, MAURO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 37.194
EU - Europa 29.383
AS - Asia 12.732
SA - Sud America 2.488
AF - Africa 271
OC - Oceania 42
Continente sconosciuto - Info sul continente non disponibili 29
AN - Antartide 1
Totale 82.140
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 36.875
GB - Regno Unito 9.233
CN - Cina 5.380
RU - Federazione Russa 4.995
SG - Singapore 4.054
IE - Irlanda 3.650
UA - Ucraina 2.759
BR - Brasile 2.159
SE - Svezia 2.073
IT - Italia 1.983
DE - Germania 1.766
FR - Francia 1.399
HK - Hong Kong 1.039
FI - Finlandia 798
KR - Corea 702
VN - Vietnam 535
IN - India 258
CA - Canada 171
TR - Turchia 143
ES - Italia 142
AR - Argentina 124
NL - Olanda 112
BD - Bangladesh 107
BE - Belgio 92
MX - Messico 91
PL - Polonia 91
IQ - Iraq 76
JP - Giappone 68
ZA - Sudafrica 65
CI - Costa d'Avorio 62
CZ - Repubblica Ceca 57
EC - Ecuador 52
ID - Indonesia 50
PK - Pakistan 40
AT - Austria 38
VE - Venezuela 38
MA - Marocco 36
SA - Arabia Saudita 34
AU - Australia 32
LT - Lituania 30
CO - Colombia 26
TN - Tunisia 26
EU - Europa 25
IR - Iran 24
UZ - Uzbekistan 24
AE - Emirati Arabi Uniti 22
GR - Grecia 22
EG - Egitto 21
PY - Paraguay 21
CH - Svizzera 20
KE - Kenya 20
PE - Perù 20
KZ - Kazakistan 19
CL - Cile 18
BG - Bulgaria 17
IL - Israele 17
NP - Nepal 17
UY - Uruguay 17
JO - Giordania 16
DK - Danimarca 15
DZ - Algeria 13
MY - Malesia 13
DO - Repubblica Dominicana 12
RO - Romania 12
AZ - Azerbaigian 11
BO - Bolivia 10
AL - Albania 9
KG - Kirghizistan 9
PH - Filippine 9
PT - Portogallo 9
JM - Giamaica 8
KW - Kuwait 8
SK - Slovacchia (Repubblica Slovacca) 8
TT - Trinidad e Tobago 8
HU - Ungheria 7
RS - Serbia 7
AM - Armenia 6
LB - Libano 6
LU - Lussemburgo 6
LV - Lettonia 6
NZ - Nuova Zelanda 6
OM - Oman 6
PA - Panama 6
BH - Bahrain 5
HR - Croazia 5
CR - Costa Rica 4
CY - Cipro 4
EE - Estonia 4
ET - Etiopia 4
IM - Isola di Man 4
KH - Cambogia 4
LA - Repubblica Popolare Democratica del Laos 4
LK - Sri Lanka 4
TW - Taiwan 4
BB - Barbados 3
BY - Bielorussia 3
GT - Guatemala 3
HN - Honduras 3
MK - Macedonia 3
SN - Senegal 3
Totale 82.075
Salva come PNG Salva come JPEG
Città #
Southend 8.589
Dallas 4.361
Fairfield 3.997
Dublin 3.610
Ashburn 2.660
Menlo Park 2.428
Singapore 2.286
Chandler 2.262
Jacksonville 2.233
Woodbridge 1.904
Houston 1.874
Wilmington 1.547
Seattle 1.492
Cambridge 1.342
Beijing 1.334
Santa Clara 1.316
Moscow 1.306
Ann Arbor 1.163
Hong Kong 1.028
Nanjing 763
Princeton 735
Seoul 681
Hefei 611
Siena 529
New York 421
Los Angeles 388
Boardman 336
San Mateo 316
The Dalles 294
Helsinki 281
Munich 278
Nanchang 251
San Diego 250
Buffalo 230
São Paulo 200
Dearborn 180
Shenyang 178
Columbus 169
Düsseldorf 162
Ho Chi Minh City 161
Shanghai 141
Council Bluffs 138
Tianjin 133
Changsha 130
Hebei 127
Venezia 107
Jiaxing 106
Hanoi 104
Milan 99
Málaga 96
Rome 94
Dong Ket 90
Kunming 89
Turku 89
London 88
Brussels 87
Lancaster 86
Jinan 83
Toronto 76
Guangzhou 75
San Francisco 73
Rio de Janeiro 71
Bengaluru 69
Redondo Beach 68
Norwalk 66
Belo Horizonte 65
Warsaw 65
Zhengzhou 65
Brooklyn 63
Abidjan 62
Izmir 60
Washington 60
Tokyo 56
Saint Petersburg 53
Chicago 50
Hangzhou 50
Mestre 50
Ningbo 50
Denver 49
Montreal 45
Stockholm 45
Changchun 44
Falls Church 44
Boston 42
Redwood City 42
Florence 41
Frankfurt am Main 41
Brasília 40
Johannesburg 38
Orem 37
Chennai 36
Poplar 36
Taizhou 36
Atlanta 34
Campinas 34
Phoenix 32
Curitiba 29
Lanzhou 29
Guarulhos 27
Bologna 26
Totale 58.107
Salva come PNG Salva come JPEG
Nome #
UNIREUMA -REUMATOLOGIA PER STUDENTI E MEDICI DI MEDICINA GENERALE I EDIZIONE 545
Comparison of combination therapies in the treatment of rheumatoid arthritis :leflunomide-anti-TNF-alfa versus methotrexate-anti-TNF-alfa 445
null 412
Livello sierico della COMP (Cartilage Oligomeric Matrix Protein): Uso potenziale come marker di progressione del danno articolare nei pazienti con "Early Rheumatoid Arthritis" 407
A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study 375
Arrhythmogenicity of Anti-Ro/SSA antibodies in patients with torsades de pointes 370
Adenosine A2A receptor activation stimulates collagen production in sclerodermic dermal fibroblasts either directly and through a cross-talk with the cannabinoid system 368
Ajulemic acid exerts potent anti-fibrotic effect during the fibrogenic phase of bleomycin lung 350
Cumulative retention rate of adalimumab in patients with Behçet's disease-related uveitis: A four-year follow-up study 330
A "new" technique for the diagnosis of chondrocalcinosis of the knee: sensitivity and specificity of high-frequency ultrasonography 328
AB0969 Accuracy of blind intra-articular injections in patients with osteoarthritis of the knee. An ultrasonography controlled study 327
Expression of RXFP1 in skin of scleroderma patients and control subjects 326
AB0535 Effects of tocilizumab on bone density and metabolism in patients with active rheumatoid arthritis 319
Antiarrhythmic potential of anticytokine therapy in rheumatoid arthritis: tocilizumab reduces corrected QT interval by controlling systemic inflammation 315
Alkaptonuria is a novel human secondary amyloidogenic disease 311
Eosinophilia-associated muscle disorders:an immunohistological study with tissue localisation of major basic protein in distinct clinicopathological forms 309
Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitis 300
The purinergic P2×7 receptor is expressed on monocytes in Behçet's disease and is modulated by TNF-α 299
Ten-Year Retention Rate of Infliximab in Patients with Behçet’s Disease-Related Uveitis 299
Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients 297
Adalimumab effectiveness in Behçet’s disease: short and long-term data from a multicenter retrospective observational study 297
A novel ex vivo organotypic culture model of alkaptonuria-ochronosis 295
Bone mineral density in patients with systemic sclerosis. 295
Association between high sensitivity C-reactive protein, heart rate variability and corrected QT interval in patients with chronic inflammatory arthritis. 295
Biological therapies for the treatment of Behçet's disease-related uveitis beyond TNF-alpha blockade: a narrative review 294
A case of amyloid myopathy in a patient with familial Mediterranean fever 292
Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry 289
Anti-Ro/SSA-associated corrected QT interval prolongation in adults: the role of antibody level and specificity 288
Change perspective to increase diagnostic accuracy of ultrasonography in calcium pyrophosphate dehydrate deposition disease! A new approach: The axial scan of the meniscus 287
Auditory involvement in Behcet’s disease: relationship with demographic, clinical, and therapeutic characteristics 286
Deltoideal acromial enthesopathy in ankylosing spondylitis and in spondylarthropathies: comment on the article by Lambert et al. 283
Circulating levels of adiponectin, resistin, and visfatin after mud-bath therapy in patients with bilateral knee osteoarthritis 283
Intravenous immunoglobulins and antiphospholipid syndrome: How, when and why? A review of the literature 282
AB1308 Prevalence of baker’s CYST in patients with chronic gonalgia and relationship with major non inflammatory diseases 282
Obesity reduces the response rate to anti TNFα in rheumatoidarthritis. an approach to a personalized medicine 281
A whitish-creamysynovial fluid. 278
Biological treatments: new weapons in the management of monogenic autoinflammatory disorders 277
Biochemical investigation of the effects of human platelet releasates on human articular chondrocytes 277
Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis 276
High levels of maternal serum IL-17 and activin A in pregnant women affected by systemic lupus erythematosus 276
Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis 274
Absence of anti-cyclic citrullinated peptide antibodies in erosive osteoarthritis: further serological evidence of the disease as a subset of osteoarthritis 273
Colchicine myopathy and neuromyopathy: two cases with different characteristics 270
Anti-cofactor autoantibodies in systemic lupus erythematosus: prevalence, clinical and HLA class II associations 270
Systemic lupus erythematosus in Europe at the change of the millennium: lessons from the "Euro-Lupus Project" 269
A case of resistant adult-onset periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis (PFAPA) syndrome responsive to anakinra. 267
Validation of a diagnostic score for the diagnosis of autoinflammatory diseases in adults 266
Low serum level of COMP, a cartilage turnover marker, predicts rapid and high ACR70 response to adalimumab therapy in rheumatoid arthritis 265
Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapies 264
Safety of cyclosporin A in HCV-infected patients: experience with cyclosporin A in patients affected by rheumatological disorders and concomitant HCV infection 261
FRI0501 Ultrasound versus synovial fluid analysis for the diagnosis of calcium pyrophosphate dihydrate deposition disease: preliminary results 260
Validation of an Italian version of the functional index for hand osteoarthritis (FIHOA) 258
Ultrasonography and magnetic resonance imaging of heel fat pad inflammatory-oedematous lesions in rheumatoid arthritis 257
Autoantibody-mediated cardiac arrhythmias: mechanisms and clinical implications 256
Diagnosis of calcium pyrophosphate dihydrate crystal deposition disease: ultrasonographic criteria proposed. 256
Could oxidative stress regulate the expression of microRNA-146a and microRNA-34a in human osteoarthritic chondrocyte cultures? 256
Quality of life impairment in Behçet’s disease and relationship with disease activity: a prospective study 252
Caveats and truths in genetic, clinical, autoimmune and autoinflammatory issues in Blau syndrome and early onset sarcoidosis 252
The diagnostic evaluation of patients with a suspected hereditary periodic fever syndrome: experience from a referral center in Italy 249
One-year follow-up of mud-bath therapy in patients with bilateral knee osteoarthritis: a randomized, single-blind controlled trial 247
SAT0312 Ultrasound Reliability in the Diagnosis of Calcium Pyrophosphate Deposition Disease: Agreement Between Observers and Main Causes of Discordance 244
Cyclosporine A for the treatment of autoimmune disorders in HCV infected patients 241
SAT0564 Articular Involvement in Behçet Disease: An Ultrasonographic Study 241
The Immunogenetics of the Antiphospholipid Syndrome, Anticardiolipin Antibodies, and Lupus Anticoagulant 240
Effects of tumor necrosis factor-α inhibitors in mothers and daughters concordant for HLA-B27-positive ankylosing spondylitis 240
Challenges and new horizons in the periodic fever, aphthous stomatitis, pharyngitis and adenitis (PFAPA) syndrome 240
Bone status of children born from mothers with autoimmune diseases treated during pregnancy with prednisone and/or low molecular weight heparin 239
Comparison of frequency of complex ventricular arrhythmias in patients with positive versus negative anti-Ro/SSA and connective tissue disease 237
Can hybrid hyaluronic acid represent a valid approach to treat rizoarthrosis? A retrospective comparative study 236
Granulomatosis with polyangiitis and intravenous immunoglobulins: A case series and review of the literature 234
FRI0533 Ultrasonographic Features of Joints and Entheses in Healty Children 234
Hydrostatic pressure regulates MicroRNA expression levels in osteoarthritic chondrocyte cultures via the Wnt/β-catenin pathway 232
Safety and efficacy of etanercept in children with juvenile-onset Behcets disease 231
Chromosomal abnormalities in peripheral lymphocytes from idiopathic Raynaud's phenomenon patients 231
A loss-of-function variant of PTPN22 is associated with reduced risk of systemic lupus erythematosus 231
Rapid and Sustained Efficacy of Golimumab in the Treatment of Multirefractory Uveitis Associated with Behçet’s Disease 231
Anticardiolipin and antibeta2GPI antibodies In a large series of european patients with systemic lupus erythematosus: prevalence and clinical association 230
Association of extrahepatic manifestations with HLA class II alleles and with virus genotype in HCV infected patients 229
Weekly oral alendronate in mevalonate kinase deficiency 229
Two single-nucleotide polymorphisms in the 5' and 3' ends of the osteopontin gene contribute to susceptibility to systemic lupus erythematosus 228
Anomalie cromosomiche, valutate come frequenza di micronuclei spontanei, in soggetti con fenomeno di Raynaud sospetto presclerodermico [Chromosome aberrations, valued as frequency of spontaneous micronuclei, in subjects with suspected presclerodermic Raynaud's phenomenon] 228
The Presence of Uveitis Is Associated with a Sustained Response to the Interleukin (IL)-1 Inhibitors Anakinra and Canakinumab in Behçet's Disease 226
Calcaneus ultrasonometry and dual-energy X-ray absorptiometry for the evaluation of vertebral fracture risk 226
Autoinflammatory disorders and patients with isolated serosal involvement. 224
Anti-ganglioside antibodies in a large cohort of European patients with systemic lupus erythematosus: Clinical, serological, and HLA class II gene associations 223
First report of circulating microRNAs in tumour necrosis factor receptor-associated periodic syndrome (TRAPS). 222
Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: results from the GISEA register 222
Cartilage oligomeric matrix protein level in rheumatic diseases: potential use as a marker for measuring articular cartilage damage and/or the therapeutic efficacy of treatments 222
Arrhythmic risk in rheumatoid arthritis: the driving role of systemic inflammation. 221
Chromosome aberrations in Raynaud's phenomenon 221
Predictors of sustained clinical response in patients with Behçet’s disease-related uveitis treated with infliximab and adalimumab 220
Fasitibant prevents the bradykinin andinterleukin 1β synergism on prostaglandin E(2) release and cyclooxygenase 2expression in human fibroblast-like synoviocytes 220
Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study 220
Efficacy and Safety of Adalimumab in Behçet’s disease related uveitis: a multicenter retrospective observational study 220
Treatment of rheumatic diseases in patients with HCV and HIV infection 220
SAT0530 The Useful of us in Diagnosis of Carpal Tunnel Syndrome in Diabetics: a Proposal for New Reference Values 219
Correlation of Serum Amyloid-A Levels, Clinical Manifestations, Treatment, and Disease Activity in Patients with Behçet's Disease 219
SAT0315 Calcium Pyrophosphate Dihydrate Deposition Disease: A Proposal of New Ultrasonographic Criteria for CPP Identification in the Joints 218
Systemic Steroid Sparing Effect of Intravitreal Dexamethasone Implant in Chronic Noninfectious Uveitic Macular Edema 218
Poly(ADP-ribose) polymerase activity in systemic lupus erythematosus and systemic sclerosis. 217
Totale 27.091
Salva come PNG Salva come JPEG
Categoria #
all - tutte 239.219
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 239.219
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20215.194 0 0 0 0 0 1.120 274 1.245 734 588 634 599
2021/20226.301 532 768 428 492 430 157 258 244 441 737 589 1.225
2022/20238.041 535 580 1.077 1.189 872 1.655 108 630 835 164 256 140
2023/20245.287 232 130 441 299 188 1.553 1.757 142 24 61 71 389
2024/202510.511 229 609 859 616 1.286 530 250 617 845 405 1.261 3.004
2025/202616.983 1.947 4.010 3.112 2.867 4.791 256 0 0 0 0 0 0
Totale 82.704